J. Spragg

发表

Antigenic separation of a nonkinin-generating TAMe esterase from human urinary kallikrein and immunohistochemical comparison of their localization in the kidney.

G. Pinkus, K. Austen, O. ole-MoiYoi, 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Cyclosporin A treatment of refractory rheumatoid arthritis.

M. Weinblatt, K. Austen, J. Spragg, 1987, Arthritis and rheumatism.

Kinin-generating and esterolytic activity of purified human urinary kallikrein (urokallikrein).

K. Austen, J. Spragg, O. O. Yoi, 1977, Biochemical pharmacology.

Sequential cleavage of proinsulin by human pancreatic kallikrein and a human pancreatic kininase.

G. Pinkus, D. Seldin, K. Austen, 1979, Proceedings of the National Academy of Sciences of the United States of America.

Identification of human glandular kallikrein in the beta cell of the pancreas.

G. Pinkus, K. Austen, O. ole-MoiYoi, 1979, The New England journal of medicine.

Isosorbide dinitrate and glyceryl trinitrate: demonstration of cross tolerance in the capacitance vessels.

E. R. Smith, J. Spragg, D. Manyari, 1985, The American journal of cardiology.

Interaction of human low molecular weight kininogen with human mast cell tryptase.

J. Spragg, L. Schwartz, M. Maier, 1986, Advances in experimental medicine and biology.

The inhibition of glandular kallikrein by peptide analog antagonists of bradykinin

J. Stewart, J. Spragg, R. Vavrek, 1988, Peptides.

Immunohistochemical localization of glandular kallikrein in the endocrine and exocrine human pancreas.

G. Pinkus, D. Seldin, K. Austen, 1983, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Inactivation of human high molecular weight kininogen by human mast cell tryptase.

J. Spragg, L. Schwartz, M. Maier, 1983, Journal of immunology.

Kinetic analysis of the interaction of human tissue kallikrein with single-chain human high and low molecular weight kininogens.

K. Austen, J. Spragg, M. Maier, 1983, Proceedings of the National Academy of Sciences of the United States of America.

Active site radioimmunoassay for human urokallikrein and demonstration by radioimmunoassay of a latent form of the enzyme.

K. Austen, O. ole-MoiYoi, J. Spragg, 1980, Journal of Immunology.

Kallikrein excretion in renal transplant recipients and in uninephrectomized donors.

K. Austen, J. Spragg, N. Tilney, 1985, Kidney international.

Angioedema induced by a peptide derived from complement component C2

F. Rosen, J. Spragg, E. Schneeberger, 1988, The Journal of experimental medicine.

Measurement of human urinary kallikrein and evidence for non-kallikrein urinary TAMe esterases by direct immunoassay and by affinity chromatography.

K. Austen, O. ole-MoiYoi, J. Spragg, 1979, Biochemical pharmacology.

Immunochemistry of Bradykinin and Immunologic Activation of the Kinin System

K. Austen, J. Spragg, R. Talamo, 1970 .

A Radio-Immunoassay for Bradykinin

E. Haber, K. Austen, J. Spragg, 1966 .

Sequential changes of myocardial perfusion following percutaneous transluminal coronary angioplasty a corollary of the stunned myocardium

M. Knudtson, J. Spragg, J. L. Hansen, 1984 .

Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates.

B. Binder, K. Austen, J. Spragg, 1979, The Journal of biological chemistry.

The effects of cyclosporin A on eicosanoid excretion in patients with rheumatoid arthritis.

P. Weber, M. Weinblatt, J. Spragg, 1991, Arthritis and rheumatism.

The effect of cyclosporine on urinary kallikrein excretion in patients with rheumatoid arthritis.

M. Weinblatt, K. Austen, J. Spragg, 1988, Advances in experimental medicine and biology.

[9] Latent kallikrein from human urine

J. Spragg, 1988 .

On localization of kallikrein in the human pancreas and salivary glands by direct immunofluorescence.

G. Pinkus, K. Austen, O. ole-MoiYoi, 1980, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Interaction of hageman factor dependent systems with the complement sequence

K. Austen, J. Spragg, D. Wooldridge, 1975 .

The Plasma Kinin-Forming System

J. Spragg, 1974 .

Purification of single-chain human low-molecular-weight kininogen and demonstration of its cleavage by human urinary kallikrein.

K. Austen, J. Spragg, M. Maier, 1983, Analytical biochemistry.

the preparation of human kininogen. II. Further characterization of purified human kininogen.

K. Austen, J. Spragg, 1971, Journal of immunology.

Specificity of Substrate Analogue Inhibitors of Human Urinary Kallikrein

J. Spragg, H. Okunishi, J. Burton, 1985, Hypertension.

Structural requirements for binding to antibody of sequence variants of bradykinin.

E. Haber, K. Austen, J. Spragg, 1967, Biochemistry.

Modifications in the Heterogeneity of the Antibody Response

E. Haber, K. Austen, M. Vallotton, 1967 .

Does lithium carbonate affect the ion transport abnormality in cystic fibrosis?

D. Shannon, J. Spragg, R. Anbar, 1990, Pediatric pulmonology.

Intraarticular activation of the complement system in patients with juvenile rheumatoid arthritis.

S. Ruddy, K. Austen, J. Spragg, 1976, Arthritis and rheumatism.

Production of antibody against bradykinin: demonstration of specificity by complement fixation and radio-immunoassay.

E. Haber, K. Austen, J. Spragg, 1966, Journal of immunology.

Plasma Factors: The Hageman-Factor-Dependent Pathways and the Complement Sequence

K. Austen, J. Spragg, 1977 .

Characterization of the procoagulant chain derived from human high molecular weight kininogen (Fitzgerald factor) by human tissue kallikrein.

K. Austen, J. Spragg, M. Maier, 1983, Blood.

The preparation of human kininogen and the elicitation of antibody for use in a radial immuno-diffusion assay.

E. Haber, K. Austen, J. Spragg, 1970, Journal of Immunology.

Structural requirements for binding of bradykinin to antibody. 3. The effect of carrier on antibody specificity.

K. Suzuki, E. Haber, K. Austen, 1969, Biochemistry.

Structural requirements for binding of bradykinin to antibody. II. Studies with bradykinin fragments.

K. Suzuki, E. Haber, K. Austen, 1968, Biochemistry.

Preparation of human kininogen. 3. Enzymatic digestion and modification.

K. Austen, J. Spragg, 1974, Biochemical pharmacology.

The Preparation of Human Kininogen

K. Austen, J. Spragg, 1971, Journal of Immunology.

Purification of a Plasminogen Activator from Venous Occlusion Plasma

B. Binder, J. Spragg, 1979, Thrombosis and Haemostasis.

Structural studies of human urinary kallikrein (urokallikrein).

K. Austen, O. ole-MoiYoi, J. Spragg, 1979, Proceedings of the National Academy of Sciences of the United States of America.

Inhibition of human urinary kallikrein (urokallikrein) by anti-enzyme FAB.

K. Austen, O. ole-MoiYoi, J. Spragg, 1978, Journal of immunology.

Immunologic reactivity of purified human urinary kallikrein (urokallikrein) with antiserum directed against human pancreas.

K. Austen, J. Spragg, S. Halbert, 1977, Journal of immunology.

Immunologic release of heparin from purified rat peritoneal mast cells.

K. Austen, R. Yurt, J. Spragg, 1977, Journal of immunology.

Inhibition of human and rat tissue kallikreins by peptide analog antagonists of bradykinin.

J. Stewart, J. Spragg, R. Vavrek, 1989, Advances in experimental medicine and biology.

In vivo inhibition of tissue kallikreins by kininogen sequence analogue peptides.

J. Spragg, N. Toda, H. Okunishi, 1989, Advances in experimental medicine and biology.

The Design of Substrate Analogue Tissue Kallikrein Inhibitors

J. Spragg, H. Okunishi, J. Burton, 1986 .